Relationship between serum inhibin A and B and ovarian follicle development after a daily fixed dose administration of recombinant follicle-stimulating hormone

被引:57
|
作者
Eldar-Geva, T [1 ]
Robertson, DM
Cahir, N
Groome, N
Gabbe, MP
Maclachlan, V
Healy, DL
机构
[1] Monash IVF, Clayton, Vic 3168, Australia
[2] Monash Univ, Dept Obstet & Gynecol, Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia
[3] Oxford Brookes Univ, Oxford OX3 0BP, England
来源
关键词
D O I
10.1210/jc.85.2.607
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study was to investigate the relationship of serum inhibin A and inhibin B to ovarian follicular development in women undergoing pituitary down-regulation and ovarian stimulation with a fixed daily dose of recombinant human FSH in an in vitro fertilization program. Thirty-eight patients were treated randomly with either 100 or 200 IU/day recombinant human FSH (Puregon) for a period of 9 -14 days. Serum FSH, inhibin A, inhibin B, 17 beta-estradiol, and follicular size and number were determined before FSH treatment and every second day from days 4-6 throughout FSH treatment. Serum FSH increased in a dose-related manner to reach a maximum by days 4-6 and remained unchanged over the duration of treatment. Serum inhibin A and 17 beta-estradiol also increased with increasing FSH dose and continued to rise throughout the FSH treatment period. By contrast, serum inhibin B was increased by days 4-6 at both doses of FSH to reach a maximum by days 7-8, remaining unchanged thereafter. Serum inhibin B and, to a lesser extent, inhibin ii correlated significantly with the number of oocytes retrieved even when assessed early (days 4-6) in the treatment period (inhibin B vs, number of oocytes: r = 0.89; P < 0.001; inhibin A vs. number of oocytes: r = 0.61; P < 0.05). Serum inhibin A, inhibin B, and 17 beta-estradiol were weakly correlated with the number of follicles less than 11 mm when assessed on a daily basis; stronger correlations were observed with the greater than Il-mm follicles during the late stages of treatment. It is concluded that serum inhibin B levels determined during the early stages (e.g. days 4-6) of fixed dose FSH treatment provide an early indicator of the number of recruited follicles that are destined to form mature oocytes. In this context, serum inhibin B may be of predictive value in monitoring ovarian hyperstimulation treatment for in vitro fertilization.
引用
收藏
页码:607 / 613
页数:7
相关论文
共 50 条
  • [1] Differential regulation of inhibin A and inhibin B by luteinizing hormone, follicle-stimulating hormone, and stage of follicle development
    Welt, CK
    Smith, ZA
    Pauler, DK
    Hall, JE
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (06): : 2531 - 2537
  • [2] Early follicle development alters the relationship between antral follicle counts and inhibin B and follicle-stimulating hormone levels on cycle day 3
    Grynberg, Michael
    Feyereisen, Estelle
    Scheffer, Juliano Brum
    Koutroubis, Panayotis
    Frydman, Rene
    Fanchin, Renato
    [J]. FERTILITY AND STERILITY, 2010, 93 (03) : 894 - 899
  • [3] Luteal estradiol administration strengthens the relationship between day 3 follicle-stimulating hormone and inhibin B levels and ovarian follicular status
    Fanchin, R
    Cunha, JS
    Schonäuer, LM
    Righini, C
    de Ziegler, D
    Frydman, R
    [J]. FERTILITY AND STERILITY, 2003, 79 (03) : 585 - 589
  • [4] Androgen and follicle-stimulating hormone interactions in primate ovarian follicle development
    Weil, S
    Vendola, K
    Zhou, J
    Bondy, CA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (08): : 2951 - 2956
  • [5] Relationship of estradiol and inhibin to the follicle-stimulating hormone variability in hypergonadotropic hypogonadism or premature ovarian failure
    Welt, CK
    Hall, JE
    Adams, JM
    Taylor, AE
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (02): : 826 - 830
  • [6] Association of Anti-Mullerian Hormone, Follicle-Stimulating Hormone, and Inhibin B with Risk of Ovarian Cancer in the Janus Serum Bank
    Irvin, Sarah R.
    Weiderpass, Elisabete
    Stanczyk, Frank Z.
    Brinton, Louise A.
    Trabert, Britton
    langseth, HilDe
    Wentzensen, Nicolas
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (03) : 636 - 642
  • [7] LOW SERUM INHIBIN B/FOLLICLE-STIMULATING HORMONE AND ANTI-MULLERIAN HORMONE/FOLLICLE-STIMULATING HORMONE RATIOS AS MARKERS OF DECREASED GERM CELLS IN INFANTS WITH BILATERAL CRYPTORCHIDISM
    Kato, Taiki
    Mizuno, Kentaro
    Nishio, Hidenori
    Nakane, Akihiro
    Kurokawa, Satoshi
    Kamisawa, Hideyuki
    Maruyama, Tetsuji
    Iwatsuki, Shoichiro
    Umemoto, Yukihiro
    Yasui, Takahiro
    Hayashi, Yutaro
    [J]. JOURNAL OF UROLOGY, 2021, 206 : E959 - E959
  • [8] Serum inhibin B and follicle-stimulating hormone levels as markers in the evaluation of azoospermic men: a comparison
    Halder, A
    Fauzdar, A
    Kumar, A
    [J]. ANDROLOGIA, 2005, 37 (05) : 173 - 179
  • [9] Clinical profiling of recombinant follicle-stimulating hormone (rFSH, Puregon): relationship between serum FSH and efficacy
    Mannaerts, BMJL
    Rombout, F
    Out, HJ
    Bennink, HJTC
    [J]. NEW HORIZONS IN REPRODUCTIVE MEDICINE, 1997, 12 : 169 - 179
  • [10] The relationship between basal serum inhibin B level and ovulatory prognosis in ovulation induction with low-dose step-up administration of recombinant follicle stimulating hormone
    Turhan, E.
    Kokcu, A.
    Cetinkaya, M.
    Yanik, F.
    Alper, T.
    Malatyalioglu, E.
    [J]. HUMAN REPRODUCTION, 2001, 16 : 211 - 211